← Back to Clinical Trials
Recruiting NCT06371768

NCT06371768 Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06371768
Status Recruiting
Phase
Sponsor Duke University
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2025-07-14
Primary Completion 2029-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
AYA Educational InformationAYA STEPS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 260 participants in total. It began in 2025-07-14 with a primary completion date of 2029-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.

Eligibility Criteria

Inclusion Criteria: * Diagnosed with one of the following cancers: 1) stage I-III breast cancer; 2) stage I-III colorectal cancer; 3) stage I-III sarcoma; 4) stage I-III Hodgkin or non-Hodgkin lymphoma; or 5) stage I-II testicular cancer * treated with curative intent and off therapy (with the exception of endocrine/hormonal therapy or oral targeted therapies used to prevent disease recurrence or progression) for the last three months * 1 to 5 years post-diagnosis * Able to speak and read English * Able to give informed consent Exclusion Criteria: * moderate or severe cognitive impairment * severe untreated mental illness (e.g., schizophrenia, substance use disorder) that would interfere with providing meaningful consent/study participation

Contact & Investigator

Central Contact

Caroline S Dorfman, PhD

✉ caroline.dorfman@duke.edu

📞 919-416-3473

Frequently Asked Questions

Who can join the NCT06371768 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06371768 currently recruiting?

Yes, NCT06371768 is actively recruiting participants. Contact the research team at caroline.dorfman@duke.edu for enrollment information.

Where is the NCT06371768 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT06371768 clinical trial?

NCT06371768 is sponsored by Duke University. The trial plans to enroll 260 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology